Select Your Region
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
BN40697 - A study to look at tominersen safety over 15 months in people with Huntington’s disease
Study in Huntington's Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139
Neurodegenerative Disorder Huntington Disease (HD)
Basic Details
Sponsor
Hoffmann-La Roche
Phase
Phase 2
Trial Identifier
NCT03342053, BN40697, ISIS 443139-CS2
Condition
Huntington's Disease
Official Title
An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
Study Summary
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
Eligibility Criteria
All
≥25 Years
No
Inclusion Criteria
- Must have completed dosing in ISIS 443139-CS1
Exclusion Criteria
- Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com